Publication: Multidrug resistance in cancer: Understanding molecular mechanisms, immunoprevention and therapeutic approaches
dc.contributor.author | Bin Emran, Talha | |
dc.contributor.author | Shahriar, Asif | |
dc.contributor.author | Mahmud, Aar Rafi | |
dc.contributor.author | Rahman, Tanjilur | |
dc.contributor.author | Abir, Mehedy Hasan | |
dc.contributor.author | Siddiquee, Mohd. Faijanur-Rob | |
dc.contributor.author | Ahmed, Hossain | |
dc.contributor.author | Rahman, Nova | |
dc.contributor.author | Nainu, Firzan | |
dc.contributor.author | Wahyudin, Elly | |
dc.contributor.author | Mitra, Saikat | |
dc.contributor.author | Dhama, Kuldeep | |
dc.contributor.author | Habiballah, Mahmoud M. | |
dc.contributor.author | Islam, Ariful | |
dc.contributor.author | Hassan, Mohammad Mahmudul | |
dc.contributor.buuauthor | Haque, Shafiul | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.orcid | 0000-0002-2989-121X | |
dc.date.accessioned | 2024-10-08T11:03:07Z | |
dc.date.available | 2024-10-08T11:03:07Z | |
dc.date.issued | 2022-06-23 | |
dc.description.abstract | Cancer is one of the leading causes of death worldwide. Several treatments are available for cancer treatment, but many treatment methods are ineffective against multidrug-resistant cancer. Multidrug resistance (MDR) represents a major obstacle to effective therapeutic interventions against cancer. This review describes the known MDR mechanisms in cancer cells and discusses ongoing laboratory approaches and novel therapeutic strategies that aim to inhibit, circumvent, or reverse MDR development in various cancer types. In this review, we discuss both intrinsic and acquired drug resistance, in addition to highlighting hypoxia- and autophagy-mediated drug resistance mechanisms. Several factors, including individual genetic differences, such as mutations, altered epigenetics, enhanced drug efflux, cell death inhibition, and various other molecular and cellular mechanisms, are responsible for the development of resistance against anticancer agents. Drug resistance can also depend on cellular autophagic and hypoxic status. The expression of drug-resistant genes and the regulatory mechanisms that determine drug resistance are also discussed. Methods to circumvent MDR, including immunoprevention, the use of microparticles and nanomedicine might result in better strategies for fighting cancer. | |
dc.identifier.doi | 10.3389/fonc.2022.891652 | |
dc.identifier.issn | 2234-943X | |
dc.identifier.scopus | 2-s2.0-85133816283 | |
dc.identifier.uri | https://doi.org/10.3389/fonc.2022.891652 | |
dc.identifier.uri | https://hdl.handle.net/11452/46064 | |
dc.identifier.volume | 12 | |
dc.identifier.wos | 000827820300001 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Frontiers Media Sa | |
dc.relation.journal | Frontiers In Oncology | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Epidermal-growth-factor | |
dc.subject | Cell lung-cancer | |
dc.subject | Transcriptional down-regulation | |
dc.subject | Hepatocellular-carcinoma cells | |
dc.subject | Terminal proliferation arrest | |
dc.subject | Premalignant oral lesions | |
dc.subject | Glutathione-s-transferase | |
dc.subject | Overcome drug-resistance | |
dc.subject | Cytotoxic t-lymphocytes | |
dc.subject | Tumor-necrosis-factor | |
dc.subject | Multidrug resistance | |
dc.subject | Cancer | |
dc.subject | Immuno-prevention | |
dc.subject | Microrna | |
dc.subject | Intracellular and extracellular atp | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Oncology | |
dc.title | Multidrug resistance in cancer: Understanding molecular mechanisms, immunoprevention and therapeutic approaches | |
dc.type | Review | |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültesi | |
local.indexed.at | WOS | |
local.indexed.at | Scopus |
Files
Original bundle
1 - 1 of 1